19 completed, 8 unknown, 3 not yet recruiting, 2 active not recruiting. 35 Phase 3, 7 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 35 | Completed 19, Unknown 8, Not yet recruiting 3, Active not recruiting 2, Terminated 2, Recruiting 1 |
| Phase 2 | 7 | Unknown 6, Recruiting 1 |
Follow Intracranial Arteriosclerosis: new trials by email Literature Review of Intracranial Arteriosclerosis trials Research Report on Intracranial Arteriosclerosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Combination Antithrombotic Treatment for Prevention of Recurrent Ischemic Stroke in IntraCranial Atherosclerotic diseaSe (CATIS- ICAS) Rivaroxaban, ASA - Ischemic Stroke, Intracranial Atherosclerosis | Phase 3 | Not yet recruiting | Population Health Research Institute | 1172 | 2026-09-30 | 2026-09-01 |
| Role of GLP1 RA Dulaglutide on Severe Intracranial Atherosclerosis Dulaglutide - Intracranial Atherosclerosis, Stroke, Ischemic | Phase 2 / Phase 3 | Recruiting | National University of Singapore | 130 | 2025-12-17 | 2025-12-23 |
| Interleukin-6 Receptor Inhibition for Symptomatic Intracranial Atherosclerosis Tocilizumab, NaCl 0.9% 100ml - Brain Diseases, Ischemic Stroke | Phase 3 | Not yet recruiting | Zhujiang Hospital | 486 | 2025-10-30 | 2025-07-28 |
| A Randomized Trial of the Rapamycin Target Eluting Stent for the Treatment of Symptomatic Cerebral Artery Atherosclerotic Disease（TARGET-DREAM） Experimental Device A, a self-expanding rapamycin target-eluting stent (MicroPort NeuroTech, Shanghai, China), Experimental Device B, a balloon-expandable rapamycin target-eluting stent (MicroPort NeuroTech, Shanghai, China), Apollo® Intracranial Artery Stent System, a balloon-expandable bare-metal stent (MicroPort NeuroTech, Shanghai, China), - Intracranial Arteriosclerosis | Phase 3 | Not yet recruiting | MicroPort NeuroTech Co., Ltd. | 279 | 2025-04-15 | 2025-04-13 |
| Cannabidiol's Role in Dementia Management Cannabidiol Oil - Dementia, Vascular, Dementia, Mixed | Phase 2 / Phase 3 | Unknown | Hospital Pengajar Universiti Putra Malaysia | 486 | 2024-09-01 | 2024-07-23 |
| Anticoagulation Using Rivaroxaban on Top of Aspirin in Intracranial Atherosclerotic Stenosis Rivaroxaban, Clopidogrel, Aspirin - Ischemic Stroke, Intracranial Atherosclerosis | Phase 2 / Phase 3 | Unknown | The First Affiliated Hospital with Nanjing Medical University | 1180 | 2023-12-30 | 2023-12-21 |
| Extra Alirocumab in Addition to Statin Therapy in Asymptomatic Intracranial Atherosclerotic Stenosis (EAST-aICAS) Alirocumab, Atorvastatin - Intracranial Atherosclerosis, Atherosclerotic Plaque | Phase 3 | Unknown | The First Affiliated Hospital with Nanjing Medical University | 80 | 2023-12-30 | 2023-12-21 |
| Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis Ticagrelor + Aspirin, Rivaroxaban + Aspirin, Clopidogrel + Aspirin - Intracranial Arteriosclerosis, Stroke | Phase 3 | Active not recruiting | University of Florida | 1683 | 2022-08-02 | 2026-10-26 |
| Prospekta in the Treatment of Cognitive, Behavioral and Psychiatric Disorders in Patients With Vascular Dementia. Prospekta, Placebo - Vascular Dementia | Phase 3 | Completed | Materia Medica Holding | 406 | 2020-12-03 | 2024-10-28 |
| Dapagliflozin Effect in Cognitive Impairment in Stroke Trial Dapagliflozin 10mg Tab, Statins (Cardiovascular Agents), Platelet Antiaggregant - Stroke, Ischemic, Mild Cognitive Impairment | Phase 2 / Phase 3 | Unknown | Jaime Daniel Mondragon | 270 | 2020-08-01 | 2022-10-04 |
| Triple Therapy Prevention of Recurrent Intracerebral Disease EveNts Trial (TRIDENT) Cognitive Sub-Study telmisartan 20mg + amlodipine 2.5mg +indapamide 1.25mg, Placebo oral capsule - Cognitive Decline, Intracerebral Hemorrhage | Phase 3 | Terminated | The George Institute | 1 | 2020-02-27 | 2021-04-01 |
| Efficacy and Safety of Butylphthalide Soft Capsule for the Treatment of Vascular Dementia Butylphthalide soft capsule, Placebo soft capsule - Vascular Dementia | Phase 3 | Active not recruiting | Capital Medical University | 707 | 2019-10-29 | 2026-03-23 |
| The Clinical Trial of Chinese Herbal Medicine (SaiLuoTong) Capsule SaiLuoTong capsule, placebo - Vascular Dementia | Phase 3 | Completed | Shineway Pharmaceutical Co.,Ltd | 493 | 2019-04-10 | 2026-02-17 |
| Local Study of Akatinol Memantine in VaD in Russia Akatinol Memantine 20 mg, Akatinol Memantine 10 mg - Vascular Dementia | Phase 3 | Completed | Merz Pharmaceuticals GmbH | 130 | 2018-01-23 | 2022-07-22 |
| Relapse Prevention Study of Pimavanserin in Dementia-related Psychosis Placebo, Pimavanserin 34 mg, Pimavanserin 20 mg - Dementia-related Psychosis | Phase 3 | Completed | ACADIA Pharmaceuticals Inc. | 392 | 2017-09-27 | 2021-06-21 |
| Optimized Remote Ischemic Conditioning (RIC) Treatment for Patients With Chronic Cerebral Ischemia Remote ischemic conditioning - Chronic Cerebral Ischemia, Intracranial Atherosclerosis | Phase 2 / Phase 3 | Unknown | Capital Medical University | 600 | 2017-06-01 | 2017-12-05 |
| The Healthy Patterns Sleep Study Attention-Control Condition, Timed Activity Intervention - Dementia, Alzheimer Disease | Phase 3 | Completed | University of Pennsylvania | 421 | 2016-05-01 | 2024-07-26 |
| Angioplasty and Stenting for Patients With Symptomatic Intracranial Atherosclerosis Percutaneous transluminal angioplasty and stenting, Aspirin plus clopidogrel - Intracranial Atherosclerosis | Phase 3 | Unknown | The 476th Hospital of People's Liberation Army | 394 | 2016-04-01 | 2016-04-05 |
| Symptomatic Treatment of Vascular Cognitive Impairment Galantamine, Methylphenidate, Placebo - Mild Cognitive Impairment (Vascular), Mild Cognitive Disorder (Vascular) | Phase 2 / Phase 3 | Unknown | Amsterdam UMC, location VUmc | 30 | 2014-02-01 | 2016-05-02 |
| Efficacy and Safety of Tianzhi Granule in Mild to Moderate Vascular Dementia Tianzhi granule and placebo identified to donepezil, Donepezil and placebo identified to Tianzhi granule, Placebo - Vascular Dementia | Phase 3 | Completed | Dongzhimen Hospital, Beijing | 543 | 2013-10-01 | 2020-01-07 |
Showing 20 of 35. Sign in to see all of them.
Dementia, Vascular (24) · Dementia (11) · Alzheimer Disease (9) · Mixed Dementias (6) · Ischemic Stroke (5) · Stroke (5) · Cognitive Dysfunction (4) · Lewy Body Disease (3) · Memory Disorders (3) · Cerebrovascular Disorders (2) · Constriction, Pathologic (2) · Neurocognitive Disorders (2) · Psychomotor Agitation (2) · Arterial Occlusive Diseases (1)
Arteriosclerosis (35) · Central Nervous System Diseases (35) · Intracranial Arterial Diseases (35) · Nervous System Diseases (35) · Vascular Diseases (35) · Arterial Occlusive Diseases (34) · Brain Diseases (34) · Cardiovascular Diseases (34) · Cerebrovascular Disorders (33) · Leukoencephalopathies (24) · Mental Disorders (24) · Neurocognitive Disorders (22) · Dementia (13) · Neurodegenerative Diseases (10)
Aspirin (4) · Clopidogrel (4) · Donepezil (3) · Galantamine (3) · Risperidone (3) · Rivaroxaban (3) · Atorvastatin (2) · Rivastigmine (2) · Amlodipine (1) · Angioplasty (1) · Biguanides (1) · Bromocriptine (1) · Cannabidiol (1) · Cardiovascular Agents (1) · Cilostazol (1)
Capital Medical University (2) · Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (2) · The First Affiliated Hospital with Nanjing Medical University (2) · ACADIA Pharmaceuticals Inc. (1) · Amsterdam UMC, location VUmc (1) · AstraZeneca (1) · Bruce Pollock (1) · Dongzhimen Hospital, Beijing (1) · Eisai Inc. (1) · GE Healthcare (1) · Hospital Pengajar Universiti Putra Malaysia (1) · Jaime Daniel Mondragon (1) · Janssen Pharmaceutica N.V., Belgium (1) · Janssen, LP (1) · Janssen-Cilag Pty Ltd (1)
China (6) · United States (6) · Germany (3) · Russia (3) · Australia (2) · Canada (2) · France (2) · Italy (2) · Netherlands (2) · Spain (2) · United Kingdom (2) · Austria (1) · Bulgaria (1) · Chile (1) · Czechia (1)
Brian L. Hoh, MD, MBA (1) · Bruce G. Pollock, M.D., Ph.D. (1) · David Blankenhorn (1) · Hang Lin, MD (1) · Holly Posner (1) · Jianmin Liu (1) · Jianping Jia, MD,PhD (1) · Jianping Jia, Professor (1) · Jinzhou Tian, MD,PhD (1)
PMID 10084637, PMID 10496251, PMID 11965273, PMID 12633121, PMID 18674411, PMID 20204386, PMID 23040716, PMID 24993764, PMID 27852711, PMID 28095900, PMID 28950419, PMID 29016744, PMID 29371333, PMID 29446769, PMID 29559423, PMID 29573529, PMID 31236801, PMID 31248555, PMID 31535829, PMID 31910895, PMID 32054507, PMID 32115470, PMID 32144994, PMID 32178931, PMID 32317958, PMID 32352644, PMID 32559474, PMID 32854852, PMID 33030307, PMID 33282811, PMID 33853394, PMID 33894597, PMID 34289275, PMID 34344312, PMID 34813630, PMID 34934801, PMID 36791792, PMID 39182330, PMID 39498781, PMID 40049590, PMID 41286676
2017 (1), P01HL023619 (1), R01MH059666 (1), R01NR015226 (1), U01NS117450 (1)